SUBSCRIBE
SUBSCRIBE
News   Policy

Sanofi-Aventis (France)'s Multaq to get U.S. Panel Review in March

December 1, 2008 | 
1 min read
PARIS, Nov 27 (Reuters) - Sanofi-Aventis' experimental heart drug Multaq will be reviewed by an independent expert panel in the United States next March, marking a delay in a priority review by the health regulator.
Regulatory Europe
Sanofi (France)
MORE ON THIS TOPIC
Health and Human Services Secretary Robert F. Kennedy Jr. makes remarks at an event announcing the MAHA (Make America Healthy Again) Commission, Thursday, May 22, 2025, in the East Room of the White House. (Official White House Photo by Joyce N. Boghosian)
Legal
Medical Groups Sue RFK Jr. Over ‘Baseless and Uninformed’ Changes to COVID-19 Vaccine Policy
July 8, 2025
 · 
2 min read
 · 
Tristan Manalac
Success to win in business competition, overcome obstacles or motivation to solve problem and lead company achievement concept, confident businessman leader jump high over 3 hurdles to be winner.
Approvals
KalVista Wins OK for First On-Demand Hereditary Angioedema Pill
July 7, 2025
 · 
2 min read
 · 
Tristan Manalac
Entrance to the U.S. Department of Health and Human Services in Washington, DC
Layoffs
HHS Cuts and Rehires by the Numbers: What We Know About Kennedy’s Overhaul
July 7, 2025
 · 
3 min read
 · 
Tristan Manalac
Close-Up Of Syringe With Bottles Against Blue Background
RSV
Kennedy Follows RSV Recommendations of ACIP Members He Fired
July 3, 2025
 · 
3 min read
 · 
Tristan Manalac